Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
JE Chaft, A Rimner, W Weder, CG Azzoli… - Nature reviews Clinical …, 2021 - nature.com
The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary
discussions of surgical resectability and medical operability determine the modality of …
discussions of surgical resectability and medical operability determine the modality of …
[HTML][HTML] Recurrence after surgery in patients with NSCLC
H Uramoto, F Tanaka - Translational lung cancer research, 2014 - ncbi.nlm.nih.gov
Surgery remains the only potentially curative modality for early-stage non-small cell lung
cancer (NSCLC) patients and tissue availability is made possible. However, a proportion of …
cancer (NSCLC) patients and tissue availability is made possible. However, a proportion of …
[HTML][HTML] Detection and characterization of lung cancer using cell-free DNA fragmentomes
D Mathios, JS Johansen, S Cristiano, JE Medina… - Nature …, 2021 - nature.com
Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for
cancer detection and intervention. Here, we use a machine learning model for detecting …
cancer detection and intervention. Here, we use a machine learning model for detecting …
[HTML][HTML] Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
SJ Antonia, A Villegas, D Daniel… - … England Journal of …, 2017 - Mass Medical Soc
Background Most patients with locally advanced, unresectable, non–small-cell lung cancer
(NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy …
(NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy …
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a …
JF Vansteenkiste, BC Cho, T Vanakesa… - The lancet …, 2016 - thelancet.com
Background Fewer than half of the patients with completely resected non-small-cell lung
cancer (NSCLC) are cured. Since the introduction of adjuvant chemotherapy in 2004, no …
cancer (NSCLC) are cured. Since the introduction of adjuvant chemotherapy in 2004, no …
[PDF][PDF] PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in …
S Senan, A Brade, L Wang… - Journal of clinical …, 2016 - researchgate.net
Purpose The phase III PROCLAIM study evaluated overall survival (OS) of concurrent
pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation …
pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation …
SPACE–a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC
J Nyman, A Hallqvist, JÅ Lund, OT Brustugun… - Radiotherapy and …, 2016 - Elsevier
Background Stereotactic body radiotherapy (SBRT) has been introduced for small lung
tumors due to excellent local control and few side effects, even though there are no …
tumors due to excellent local control and few side effects, even though there are no …
[HTML][HTML] 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
WEE Eberhardt, D De Ruysscher, W Weder… - Annals of …, 2015 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
[HTML][HTML] 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
J Vansteenkiste, L Crino, C Dooms, JY Douillard… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
[PDF][PDF] Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA (N2) and selected IIIB non–small-cell lung …
WEE Eberhardt, C Pöttgen, TC Gauler… - Journal of Clinical …, 2015 - researchgate.net
Purpose Concurrent chemoradiotherapy with or without surgery are options for stage IIIA
(N2) non–smallcell lung cancer. Our previous phase II study had shown the efficacy of …
(N2) non–smallcell lung cancer. Our previous phase II study had shown the efficacy of …